Taiho Oncology is pleased to announce the commercial availability of LYTGOBI® (futibatinib) tablets. As we are ramping up to full supply, currently the 4mg tablet 35-count DosePak is available for prescribing via Onco360. The remaining two packages, 4mg tablet 28-count DosePak and 4mg tablet 21-count DosePak, will be available on or before April 1, 2023. At that time oncology clinic and hospital outpatient pharmacies will be able to place orders through their specialty distributor, similar to the ordering process for Taiho Oncology’s products Lonsurf and INQOVI.

For any questions related to the availability of LYTGOBI or the Taiho Oncology Patient Assistance program for LYTGOBI please call 844-TAIHO-4U (844-824-4648). Onco360 may be contacted at 877-662-6633 (phone), 877-662-6355 (fax), or www.onco360.com.